Expanded Access

Akamis Bio is committed to developing innovative therapeutics for patients with cancer. Our pipeline of T-SIGn® therapeutics are considered investigational, which means that they have not been approved by regulatory authorities.

Akamis Bio is not currently making any of its investigational therapeutics available on an Expanded Access basis. Patients interested in learning if enrolment in a clinical trial is an option for them should consult with their treating physician.

Akamis Bio is a clinical-stage oncology company whose mission is to positively impact the lives of people living with cancer.

We currently have an early stage investigational medicine in our product pipeline for the treatment of locally advanced rectal cancer. Our goal is to provide access to our medicine at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe enrollment in our ongoing clinical trial is the safest and most effective way of
achieving this goal.

We do recognize that some patients will not be eligible for our clinical trial and may wish to access our product through expanded access. However, at this time, we do not have the resources available to offer expanded access use of our investigational medicine.

We encourage all patients and physicians who are interested in accessing our investigational medicine and finding out about enrolling in our clinical trial to visit the patients section of our website at www.akamisbio.com/patients.

Akamis Bio may revise this expanded access policy at any time. Additionally, the posting of this policy by Akamis Bio does not serve as a guarantee of access to any specific investigational new drug by any individual patient.

If you have any questions, please reach out to us at robert.maietta@akamisbio.com. You can find further contact details on our website at www.akamisbio.com/contact.